What is CorMedix's market cap?

CorMedix (CRMD) has a market capitalization of $680.2M and trades on NASDAQ.

What is CorMedix's revenue and profitability?

CorMedix generated $400.1M in trailing twelve-month revenue with net income of $181.0M, representing a net margin of 45.2%. Gross margin stands at 91.9%, with free cash flow of $194.7M. These figures are based on the Q1 2026 filing.

Who are CorMedix's competitors?

CorMedix's key competitors include Merck & Co., Pfizer Inc., CalciMedica, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does CorMedix partner with?

CorMedix's notable partners include Biomedical Advanced Research and Development Authority, Mundipharma, Rovi Pharma Industrial Services, and others.

What subsidiaries does CorMedix have?

CorMedix's subsidiaries include Melinta Therapeutics, LLC.

Where is CorMedix headquartered?

CorMedix is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 2010.

CorMedix

CRMD

Market cap

$680.18M-22.0%

Revenue$400.1M+385%

Net income$181.0M+1,784%

Free cash flow$194.7M+1,528%

EPS (diluted)$2.04+916%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$127.4MBeat by $22.4M EPS$0.43Beat by $0.08

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$96.0M

EPS estimate$0.26

Financials

Q1 2026

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation & ratios

Valuation

See full

Market cap$680.18M-22.0%

P/E3.8×—

P/S1.7×-5.3×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Current ratio3×-1.2×

Segments

By product

See full

DefenCath$97.5M+150%

Melinta Portfolio$24.4M—

Contract revenue$5.5M—

Competitors

By market cap

Merck & Co.$308.90B+52.1%

Pfizer$138.21B-3.7%

Merit Medical Systems$4.3B-20.8%

IAR

Integra LifeSciences$1.4B+44.4%

CorMedix$680.2M-20.0%

Seres Therapeutics$65.3M-31.1%

Citius Pharmaceuticals$15.4M-34.5%

CalciMedica$15.0M-33.3%

By revenue growth

CorMedix+385%

Merit Medical Systems+11.1%

Merck & Co.+2.9%

Pfizer+1.4%

IAR

Integra LifeSciences+1.2%

By net margin

CorMedix45.25%+58.3pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Merit Medical Systems9.03%+0.2pp

IAR

Integra LifeSciences-30.15%-27.0pp

Profile

CorMedix Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for life-threatening diseases, with a primary focus on infectious diseases and cardiovascular health. The company's core value proposition centers on its portfolio of hospital- and clinic-focused anti-infectives, including the first FDA-approved antimicrobial catheter lock solution designed to reduce bloodstream infections in hemodialysis patients. Following a significant acquisition, the company has expanded its commercial platform to address serious fungal and bacterial infections within the hospital ecosystem.

Competitive position

CorMedix holds a first-mover advantage with the only FDA-approved antimicrobial catheter lock solution in the U.S. and maintains a diversified anti-infective portfolio through its acquisition of Melinta Therapeutics.

GeographiesUnited States

Customer segmentsHospitals, Dialysis Centers, Government Agencies

Business modelProduct-based, Licensing, Research and Development

SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Third-party logistics providers

CustomersDialysis organizations, Hospital pharmacy and therapeutics committees, Government healthcare programs (Medicare/Medicaid), Commercial insurers

CountryUnited States of America

Listed2010

Employees82.0

CEOJoseph Todisco

SectorHealthcare

IndustryBiotechnology

Websitecormedix.com

FilingsSEC EDGAR

Ask your AI about CorMedix.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's market cap?: CorMedix (CRMD) has a market capitalization of $680.2M and trades on NASDAQ.
What is CorMedix's revenue and profitability?: CorMedix generated $400.1M in trailing twelve-month revenue with net income of $181.0M, representing a net margin of 45.2%. Gross margin stands at 91.9%, with free cash flow of $194.7M. These figures are based on the Q1 2026 filing.
Who are CorMedix's competitors?: CorMedix's key competitors include Merck & Co., Pfizer Inc., CalciMedica, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does CorMedix partner with?: CorMedix's notable partners include Biomedical Advanced Research and Development Authority, Mundipharma, Rovi Pharma Industrial Services, and others.
What subsidiaries does CorMedix have?: CorMedix's subsidiaries include Melinta Therapeutics, LLC.
Where is CorMedix headquartered?: CorMedix is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 2010.